Catalyst Pharmaceuticals Inc (CPRX)
21.12
-0.03
(-0.14%)
USD |
NASDAQ |
Nov 21, 16:00
21.12
0.00 (0.00%)
After-Hours: 20:00
Catalyst Pharmaceuticals Enterprise Value: 2.077B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 2.077B |
| November 20, 2024 | 2.080B |
| November 19, 2024 | 2.109B |
| November 18, 2024 | 2.041B |
| November 15, 2024 | 2.015B |
| November 14, 2024 | 2.145B |
| November 13, 2024 | 2.277B |
| November 12, 2024 | 2.306B |
| November 11, 2024 | 2.355B |
| November 08, 2024 | 2.412B |
| November 07, 2024 | 2.331B |
| November 06, 2024 | 2.266B |
| November 05, 2024 | 2.177B |
| November 04, 2024 | 2.152B |
| November 01, 2024 | 2.168B |
| October 31, 2024 | 2.158B |
| October 30, 2024 | 2.129B |
| October 29, 2024 | 2.154B |
| October 28, 2024 | 2.165B |
| October 25, 2024 | 2.117B |
| October 24, 2024 | 2.111B |
| October 23, 2024 | 2.103B |
| October 22, 2024 | 2.117B |
| October 21, 2024 | 2.065B |
| October 18, 2024 | 2.091B |
| Date | Value |
|---|---|
| October 17, 2024 | 2.081B |
| October 16, 2024 | 2.142B |
| October 15, 2024 | 2.084B |
| October 14, 2024 | 2.019B |
| October 11, 2024 | 1.967B |
| October 10, 2024 | 1.932B |
| October 09, 2024 | 1.939B |
| October 08, 2024 | 1.953B |
| October 07, 2024 | 1.911B |
| October 04, 2024 | 1.943B |
| October 03, 2024 | 1.929B |
| October 02, 2024 | 1.943B |
| October 01, 2024 | 1.969B |
| September 30, 2024 | 1.929B |
| September 27, 2024 | 1.946B |
| September 26, 2024 | 1.992B |
| September 25, 2024 | 1.998B |
| September 24, 2024 | 2.057B |
| September 23, 2024 | 2.056B |
| September 20, 2024 | 2.092B |
| September 19, 2024 | 2.158B |
| September 18, 2024 | 2.049B |
| September 17, 2024 | 2.050B |
| September 16, 2024 | 2.050B |
| September 13, 2024 | 2.024B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
175.38M
Minimum
Mar 16 2020
2.412B
Maximum
Nov 08 2024
901.28M
Average
617.23M
Median
Mar 10 2022
Enterprise Value Benchmarks
| Corcept Therapeutics Inc | 5.479B |
| Vertex Pharmaceuticals Inc | 109.46B |
| Sarepta Therapeutics Inc | 10.58B |
| ADMA Biologics Inc | 5.050B |
| BioVie Inc | 38.56M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 43.88M |
| Revenue (Quarterly) | 128.70M |
| Total Expenses (Quarterly) | 77.79M |
| EPS Diluted (Quarterly) | 0.35 |
| Gross Profit Margin (Quarterly) | 85.02% |
| Profit Margin (Quarterly) | 34.10% |
| Earnings Yield | 5.59% |
| Operating Earnings Yield | 6.76% |
| Normalized Earnings Yield | 5.599 |